Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

MAZE THERAPEUTICS, INC. (MAZE) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

MAZE THERAPEUTICS, INC. (MAZE), most recent 12 months reported: net loss $133.59M, free cash flow -$106.84M. Latest balance sheet on file: liquid cash $411.09M, total debt $38.96M, net cash $372.13M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Kyverna Therapeutics, Inc. · LIMINATUS PHARMA, INC. · LeonaBio, Inc. · Lexeo Therapeutics, Inc. · NEUMORA THERAPEUTICS, INC. · OUTLOOK THERAPEUTICS, INC. · PALISADE BIO, INC. · PASSAGE BIO, INC.

Stock screener

Watchlist